PRQR ProQR Therapeutics
- 2.0100
- +0.0200+1.01%
ProQR Therapeutics News
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 20-F: Registration statement / Annual report / Transition report
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Van Herk Investments B.V.(10.1%),Van Herk Investments THI B.V.(10.1%), etc.
ProQR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Van Herk Investments B.V.(8.8%),Van Herk Investments THI B.V.(8.8%), etc.
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Van Herk Investments B.V.(5.3%),Van Herk Investments THI B.V.(5.3%), etc.
ProQR Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ProQR Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
ProQR Therapeutics | EFFECT: Others
ProQR Therapeutics | 424B5: Prospectus
ProQR Therapeutics | CORRESP: CORRESP
Analysis
Price Target
No Data
